Table 1

The frequency a diagnosis was achieved in participants, and the frequency investigations on our guidelines were normal, abnormal non-diagnostic and diagnostic

ParticipantsDiagnosis reached?Investigations (%)
ResultFBCZPPU&ELFTBone profileTFTBiotinidaseCKLead levelPlasma amino acidsUrine organic acidsUrine GAGsKaryotypeMicroarrayFragile XMRI brain
All participants
(n=699)
166
(23.7%)
Number receiving test526/699 (75.2%)278/699 (39.8%)512/699 (73.2%)491/699 (70.2%)429/699
(61.4%)
469/699
(67.1%)
227/699
(32.5%)
388/699
(55.5%)
40/699
(5.7%)
413/699
(59.1%)
318/699
(45.4%)
217/699
(31.0%)
96/699
(13.7%)
442/699
(63.2%)
113/699
(16.2%)
368/699
(52.6%)
Normal444/526 (84.4%)205/278 (73.7%)477/512 (93.2%)434/491
(88.4%)
412/429
(96.0%)
431/469
(91.9%)
216/227
(95.2%)
340/388
(87.6%)
40/40
(100%)
392/413 (94.9%)286/318 (90.0%)200/217
(92.2%)
94/96
(97.9%)
342/442
(77.4%)
112/113
(99.1%)
208/368
(56.5%)
Abnormal: non-diagnostic82/526 (15.6%)73/278 (26.3%)35/512 (6.8%)57/491
(11.6%)
17/429
(4.0%)
35/469
(7.5%)
11/227
(4.8%)
48/388
(12.4%)
0/40
(0%)
16/413
(3.9%)
29/318
(9.1%)
17/217
(7.8%)
0/96
(0%)
49/442
(11.1%)
0/113
(0%)
75/368
(20.4%)
Abnormal: diagnostic0/526
(0%)
0/278
(0%)
0/512
(0%)
0/491
(0%)
0/429 (0%)3/469 (0.6%)*0/227
(0%)
0/388
(0%)
0/40
(0%)
5/413
(1.2%)†
3/318
(0.9%)‡
0/217
(0%)
2/96
(2.1%)
51/442
(11.5%)
1/113
(0.9%)
85/368
(23.1%)
EDI without additional features
(n=142)
14
(9.9%)
Number receiving test99/142
(69.7%)
66/142
(46.5%)
91/142
(64.1%)
87/142
(61.3%)
79/142
(55.6%)
91/142
(64.1%)
44/142
(31.0%)
80/142
(56.3%)
5/142
(3.5%)
75/142
(52.8%)
53/142
(37.3%)
38/142
(26.8%)
9/142
(6.3%)
79/142
(55.6%)
24/142
(16.9%)
30/142
(21.1%)
Normal86/99
(86.9%)
52/66
(78.8%)
90/91
(98.9%)
81/87
(93.1%)
75/79
(94.9%)
86/91
(94.5%)
44/44
(100%)
73/80
(91.3%)
5/5
(100%)
71/75
(94.7%)
50/53
(94.3%)
31/38
(81.6%)
9/9
(100%)
60/79
(75.9%)
23/24
(95.8%)
20/30
(66.7%)
Abnormal: non-diagnostic13/99
(13.1%)
14/66
(21.2%)
1/91
(1.1%)
6/87
(6.9%)
4/79
(5.1%)
5/91
(5.5%)
0/44
(0%)
7/80
(8.7%)
0/5
(0%)
4/75
(5.3%)
3/53
(5.7%)
7/38
(18.4%)
0/9
(0%)
10/79
(12.7%)
0/24
(0%)
6/30
(20.0%)
Abnormal: diagnostic0/99
(0%)
0/66
(0%)
0/91
(0%)
0/87
(0%)
0/79
(0%)
0/91
(0%)
0/44
(0%)
0/80
(0%)
0/5
(0%)
0/75
(0%)
0/53
(0%)
0/38
(0%)
0/9
(0%)
9/79
(11.4%)
1/24
(4.2%)
4/30
(13.3%)
All participants with EDI and additional features
(n=557)
152
(27.3%)
Number receiving test427/557
(76.7%)
212/557
(38.1%)
421/557
(75.6%)
404/557
(72.5%)
350/557
(62.8%)
378/557
(67.9%)
183/557
(32.9%)
308/557
(55.3%)
35/557
(6.3%)
338/557
(60.7%)
265/557
(47.6%)
179/557
(32.1%)
86/557
(15.4%)
363/557
(65.2%)
89/557
(16.0%)
338/557
(60.7%)
Normal358/428
(83.6%)
153/212
(72.2%)
387/421
(91.9%)
353/404
(87.4%)
337/350
(96.3%)
345/378
(91.3%)
172/183
(94.0%)
267/308
(86.7%)
0/35
(0%)
321/338
(94.9%)
236/265
(89.1%)
169/179
(94.4%)
84/86
(97.7%)
282/363
(77.7%)
89/89
(0%)
188/338
(55.6%)
Abnormal: non-diagnostic69/428
(16.1%)
59/212
(27.8%)
34/421
(8.1%)
51/404
(12.6%)
13/350
(3.7%)
30/378
(7.9%)
11/183
(6.0%)
41/308
(13.3%)
35/35
(100%)
12/338
(3.6%)
26/265
(9.8%)
10/179
(5.6%)
0/86
(0%)
39/363
(10.7%)
0/89
(0%)
69/338
(20.4%)
Abnormal: diagnostic0/428
(0%)
0/212
(0%)
0/421
(0%)
0/404
(0%)
0/350
(0%)
3/378
(0.8%)
0/183
(0%)
0/308
(0%)
0/35
(0%)
5/338
(1.5%)
3/265
(1.1%)
0/179
(0%)
2/86
(2.3%)
42/363
(11.6%)
0/89
(0%)
81/338
(24.0%)
  • *Thyroid function: (a) boy presented at 1 year 10 months as a placid baby with EDI most obvious in motor skills and with hypotonia. Autoimmune hypothyroidism diagnosed and he improved with treatment although subsequently developed ASD; (b) ex-preterm (29 weeks) girl investigated at 4 years 7 months to a mother with learning difficulties, had general developmental impairment, especially in speech skills who improved on treatment but had attention and behavioural difficulties; (c) girl investigated at 5 years 6 months for EDI, nystagmus with a history of maternal illicit drug use in pregnancy—showed improvement on treatment, but not to normal abilities. Dual diagnosis is being investigated.

  • †Plasma amino acids: (a) boy investigated at 4 years 1 month with EDI and seizures whose brother had similar phenotype diagnosed with homocystinuria; (b) 4-month-old boy with EDI, microcephaly, hypertonia and poor visual function with low serum and CSF serine, diagnosed with serine deficiency; (c) girl investigated at 2 years 11 months with EDI, brittle hair, eczema and dysmorphia diagnosed with ethylmalonic aciduria; (d) boy investigated at 4 years 7 months with EDI and faltering growth diagnosed with lysinuric protein intolerance; (e) boy investigated at 10 months with EDI, visual impairment and hypotonia noted to have low serum and CSF serine, diagnosed as serine deficiency.

  • ‡Urine organic acids: ex-premature girl investigated at 8 months for EDI, acquired microcephaly and faltering growth with raised lactate and glutamate, subsequently diagnosed with pyruvate dehydrogenase deficiency; see cases (c) and (d) in the plasma amino acid results.

  • ASD, Autistic spectrum disorder; CSF, cerebrospinal fluid; CK, creatine kinase; EDI, early developmental impairment; FBC, full blood count; GAG, glycosaminoglycans; LFT, liver function test; TFT, thyroid function test; U&E, urea and electrolytes; ZPP, zinc protoporphyrin;